THE doctor in charge of the reconfiguration of health services in the south has been asked to explain to a Dáil committee the existence of a “secret” group advising the Health Service Executive (HSE) on the project.

A HORSE trainer and a property developer are among a “secret” group of 17 people advising the Health Service Executive (HSE) on reconfiguration of health services in the South.

THE ISEQ index yesterday closed up 27.06 points at 2,278.03. AIB was the star performer on the ISEQ jumping 20c or 20% to close at €1.20. Bank of Ireland also had a positive day progressing 5c to 62c, Irish Life & Permanent added 11c to €1.74, while FBD Holdings was 12c lighter at €7.88.

IRISH stocks continued their advance yesterday climbing 2.6% as details of the government’s bank guarantee sank in.

The ISEQ index of Irish shares gained some ground this evening up 26 points to 4347.27 at market close.

Elan Corporation today announced its second quarter 2008 financial results and provided a business update revealing optimism following the trials of some new medication.

A DROP in oil prices and a better than expected results from US bank Wells Fargo on Wednesday evening led to a rise on worldwide stock exchanges. The ISEQ index jumped a healthy 227.47 points to finish at 4673.79.

Elan Corporation today announced its first quarter 2008 financial results and provided a business update indicating positive results.

IRISH share prices soared by 5.47% yesterday gaining €3.4 billion in value.

The ISEQ index of Irish shares closed in negative territory this evening dropping 42.29 points to 6495.39 at market close.

Elan Corporation, plc today announced its full-year and fourth quarter 2007 financial results and provided guidance for its financial outlook for 2008.

The ISEQ index of Irish shares slumped this morning by 100.02 points to 8729.65.

Elan Corporation announced yesterday, Dr Floyd Bloom, a neuro- scientist, and Jeff Shames, a retired chairman and chief executive officer of MFS Investment Management (MFS), will become new non- executive members of the board, from July 1.

Elan Corporation today announced a number of changes to its board of directors.

Elan Corporation, plc today announced its full-year and fourth quarter 2006 financial results and provided guidance for its financial outlook for 2007.

A MULTIPLE SCLEROSIS drug pulled from the US market last year is to return and has also been given preliminary approval for use in Europe, a move that will be welcomed by the 6,000 Irish people affected by the condition.

Elan Corporation and its partner Biogen Idec have confirmed that they have resumed a safety study on their controversial MS drug Tysabri.

IRISH shares surged ahead yesterday for the second consecutive day led by the financial and construction stocks. The ISEQ index closed up 37.18 points to 6437.27.

SHAREHOLDERS in the troubled Elan Corporation gather in Dublin tomorrow for the annual general meeting (AGM).

Elan Corporation, plc today announced that it has reached an agreement to settle the previously disclosed consolidated class action pending in the U.S. District Court for the Southern District of New York.

In response to a specific Irish Stock Exchange query made today, Elan Corporation, plc has advised that it is not in negotiations ordiscussions with Biogen Idec, Inc. regarding any form of merger or business combination between the two companies.

Elan Corporation will announce its interim results for the six months ended June 30, 2004 this week.

EUROPEAN markets slipped back amid continued concern about high oil prices. Shares in Dublin followed this trend, with the ISEQ index 18.68 points lower at 5302.60.

SHARES in Dublin traded solidly yesterday, with the ISEQ index finishing 14.59 points higher at 5351.51.

Biogen Idec and Elan Corporation have announced that the US Food and Drug Administration (FDA) has formally accepted their Biologics License Application (BLA) for Multiple Sclerosis drug Antegren (natalizumab).

Elan Corporation and Wyeth Pharmaceuticals last night announced key findings from a clinical trial of a new Alzheimers treatment, AN-1792, at the International Conference on Alzheimers Disease and Related Disorders in Philadelphia.

ISEQ-listed Elan Corporation today announced that it has completed the sale of its worldwide rights to Myobloc/Neurobloc injectable solution to Solstice Neurosciences a newly-formed company focused on the development, manufacturing, sales and marketing of specialty biopharmaceutical products.

The ISEQ index closed up 73.36 points at 5,449.45 at close of trading today.

Elan Corporation, the long-troubled Irish drugs maker now on the rebound, surged on stock markets today after reporting that its trial drug for treating multiple sclerosis, Antegren, has been fast-tracked for potential approval in the United States.

SHARES in Dublin saw the ISEQ index finish 8.23 points higher at 5372.76.

TRADING volumes across Europe were light yesterday with the US market closed as a mark of respect for former president Ronald Reagan.

THE ISEQ fell 30.39 points to 5155.89 yesterday.

EUROPEAN markets were in positive form yesterday with most bourses gaining around 2%.

Responding to a number of recent inquiries from the investment community, Elan Corporation has reiterated the terms of its Series Z warrants.

Dublin: Law firm Matheson Ormsby Prentice has appointed former Elan senior executive Tom Maher as a partner and head of the firm’s life sciences practice.

Elan Corporation has announced that Seamus Mulligan, executive vice president of business and corporate development, is leaving the company to pursue other opportunities within the pharmaceutical industry.

THE Dublin market finished the week on a negative note with the ISEQ index falling 12.06 points to 5041.24. The main European markets declined with the exception of the FTSE driven higher by strength in Vodafone.

Pharmaceutical company Elan Corporation, has announced the completion of the sale of its European sales and marketing business to Medeus Pharma, a new UK pharmaceutical company backed by private equity firm Apax Partners Funds.

The Irish market began the week strongly, moving in line with the major European markets.

ELAN Corporation has agreed to sell its European sales and marketing business for €100 million million to Medeus UK Limited, a new British pharmaceutical company backed by Apax Partners Funds.

YESTERDAY the ISEQ index rose to its highest level in 2003, mirroring the positive mood across Europe. The ISEQ finished 31.89 points higher at 4824.67.

THE ISEQ index rose yesterday for a second day in succession to close 16.43 points higher at 4769.49.

The ISEQ index went against the positive trend set by other European markets, falling 2.65 points to 4769.95.